.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Farmers Insurance
Johnson and Johnson
Merck
Citi
Colorcon
Fuji
US Department of Justice
QuintilesIMS
Julphar

Generated: December 17, 2017

DrugPatentWatch Database Preview

CANASA Drug Profile

« Back to Dashboard

When do Canasa patents expire, and what generic alternatives are available?

Canasa is a drug marketed by Forest Labs Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Drug patent expirations by year for CANASA

Pharmacology for CANASA

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate

Medical Subject Heading (MeSH) Categories for CANASA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs LlcCANASAmesalamineSUPPOSITORY;RECTAL021252-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
Forest Labs LlcCANASAmesalamineSUPPOSITORY;RECTAL021252-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
Forest Labs LlcCANASAmesalamineSUPPOSITORY;RECTAL021252-001Jan 5, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for CANASA

Drugname Dosage Strength RLD Submissiondate
mesalamineSuppository1000 mgCanasa5/24/2013

Non-Orange Book Patents for Tradename: CANASA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,541,384Mesalamine suppository► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CANASA

Country Document Number Estimated Expiration
European Patent Office2512443► Subscribe
Russian Federation2012125186► Subscribe
Japan2013514979► Subscribe
Mexico2012006902► Subscribe
Singapore181169► Subscribe
Mexico2012006902► Subscribe
Singapore181169► Subscribe
Israel220397► Subscribe
Canada2690450► Subscribe
Israel220397► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
Deloitte
Merck
Chubb
Healthtrust
QuintilesIMS
AstraZeneca
Johnson and Johnson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot